Visit the Centre to discover the latest innovations and advances in the omega-3 industry; download from a variety of presentations and view informative infographics; source quality ingredients for your next new product launch; meet with GOED expert staff and ask for a demo of the clinical studies database; come connect and learn about what's driving market growth in 2021.
The global EPA and DHA omega-3 market has a history that goes back to 1700’s and one that has survived a multitude of challenges over time. In these past two years we faced one of the biggest challenges to date, as the entire health and nutrition industry — and indeed the world — was forced to deal with the Covid-19 pandemic. Despite the disruptions, the nutrition industry has performed quite well, and consumers have purchased all types of health products, including omega-3s.
The EPA and DHA omega-3 industry continues to grow in almost all markets around the globe, although mature markets, like the US and EU, are relatively flat year on year. Strong scientific evidence supports the benefits of EPA and DHA omega-3s for maintaining and optimizing heart health, as well as brain health, eye health and prenatal health, and the body of evidence grows on a daily basis.
The global EPA and DHA omega-3 market at the raw material level was valued at US$1.44 billion in 2019, representing a 3.3% increase over 2018, with a corresponding volume of 112,633 metric tonnes of omega-3 oil. Europe is the second largest market behind the US, making up 26% of the volume worldwide compared to the 33% for the US. China is next with 12% of the market while Asia-Pacific makes up 9% and Japan accounts for 5%. From a value perspective, Europe and China are almost equal in terms of dollar sales — with 37% of the global market — due to China’s large market for infant formula, a premium-priced product.
At the finished products level, Europe is the second largest consumer of EPA and DHA end products, with a solid functional food market and an estimated $11.6 billion in sales.
At the finished products level, Europe is the second largest consumer of EPA and DHA end products, with a solid functional food market and an estimated $11.6 billion in sales and 26% share in 2019.
Sales of EPA/DHA supplements in Europe have reached nearly $1.1 billion but the market is primarily flat. Expanding usage in Eastern European countries is the biggest driver of the region’s forecasted growth.
Overall, growth for the European finished product market in the range of 5% is expected in the next two years. This is based on the infant formula market, with most growth expected in Eastern Europe, and a forecast of strong growth in the fortified pet food category.
Although the European market is mature, the vast majority of consumers in the region still do not get enough EPA and DHA to support their health. It’s important that the collective industry join forces in investment and strategy to bring new consumers to the category.
There has never been a better time to promote sales of EPA and DHA omega-3s and the tools to do so are readily available!
Come to the Omega-3 Resource Center (I-250) to learn more about these tools, speak with an expert from GOED, view valuable presentations on the digital display screens, and explore new omega-3 innovations from our exhibiting partners. You can also preview our ground-breaking Clinical Study Database, which catalogs all human omega-3 studies.
On behalf of GOED, we wish you a very successful show!
innovations from our exhibiting partners. You can also preview our ground-breaking Clinical Study Database, which catalogs all human omega-3 studies.
Impact Ingredients BV - STAND I250J
BRUDY TECHNOLOGY - STAND I250F
CALANUS AS - STAND I250H
GUANGXI XIAOZAO AGRICULTURAL TECHNOLOGY CO LTD - STAND I250L
HUVEPHARMA EOOD - STAND I250N
IMPERIALOEL / MARIS OMEGA-3 - STAND I250C
IFFE BIOTECH, S.L. - STAND I250I
NUTRISWISS AG - STAND I250R
PHARMA MARINE AS - STAND I250A
VITUX AS - STAND I250Q